



## HY 2022 P&L Consensus

€m	HY 2021A	HY 2022E	HY 2022E
		Average	Median
Net Sales	2,651	2,533	2,561
Revenue	2,778	2,672	2,695
Adj. EBIT	682	487	494
Adj. EBITDA	843	661	694
Net Profit*	571	363	368
Core EPS	3.40	2.39	2.44

\*attributable to UCB shareholders

## HY 2022 Product Sales Consensus

€m	HY 2021A	HY 2022E	HY 2022E
		Average	Median
Cimzia	873	963	964
Vimpat	735	592	617
Keppra	485	392	400
Neupro	158	149	151
Briavact	166	212	213
Nayzilam	21	37	38
Evenity*	4	13	12
Bimzelx		18	15
Fintepla		30	32

\*UCB sales - not enough global Evenity sales estimates available for a meaningful HY consensus

Based on the estimates of 13 brokers

Last updated: 15/07/22